Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 4/20 | 0.85 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 2/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38645 | 0.92 | GSK3B (1.00) | GSK3BPTPN1ALDH1A1MAPTGRM5 | |
| SCHEMBL29615087 | 0.92 | GSK3B (1.00) | GSK3BPTPN1ALDH1A1MAPTGRM5 | |
| SCHEMBL30239069 | 0.87 | GSK3B (0.61) | GSK3BALDH1A1MAPTGRM5GPR139 | |
| SCHEMBL39137 | 0.87 | GSK3B (0.61) | GSK3BALDH1A1MAPTGRM5GPR139 | |
| SCHEMBL18380618 | 0.84 | GSK3B (0.57) | GSK3BPTPN1ALDH1A1MAPTMEN1 | |
| SCHEMBL8489037 | 0.80 | GSK3B (0.66) | GSK3BALDH1A1MAPTGRM5GPR139 | |
| SCHEMBL12231204 | 0.79 | GSK3B (0.70) | GSK3BALDH1A1MAPTGRM5GPR139 | |
| SCHEMBL2310105 | 0.79 | GSK3B (0.70) | GSK3BALDH1A1GRM5GPR139VNN1 | |
| SCHEMBL29556203 | 0.79 | GSK3B (0.70) | GSK3BALDH1A1GRM5GPR139VNN1 | |
| SCHEMBL8105775 | 0.79 | GSK3B (0.74) | GSK3BALDH1A1MAPTGRM5GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072876-A1 | Substituted thiazole derivatives bearing 3-pyridyl groups, process for preparing the same and use thereof | CYP17A1, CYP21A2, HSD17B1 | GSK3B 1171/4885PTPN1 769/4885ALDH1A1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.